Metastatic Breast Cancer

Increasing tamoxifen dosage did not lead to a higher rate of 6-month PFS among patients with hormone receptor-positive metastatic breast cancer who have CYP2D6-variant alleles, according to results of a randomized phase 2 study.

High-dose chemotherapy followed by hematopoietic stem cell transplantation improved OS among very high-risk patients with breast cancer compared with conventional-dose chemotherapy, according to long-term follow-up of a randomized study published in JAMA Oncology.

The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who received at least two prior anti-HER2-based regimens in the metastatic setting.

Last week’s top stories in oncology were from Healio’s live coverage of the San Antonio Breast Cancer Symposium, which recently wrapped up in Texas, and the American Society of Hematology Annual Meeting and Exposition, which just concluded in Orlando.

Oncotype DX Breast Recurrence Score appeared to be associated with mortality at a lower threshold for men with breast cancer than for their female counterparts, according to results of a retrospective study published in Clinical Cancer Research.

A discussion with the author of a study that found direct-to-consumer genetic tests had an “alarming” rate of clinical false-negative results for two limited variant screening tests — including the test for BRCA1 and BRAC2 — was last week’s top story in hematology/oncology.

The addition of tucatinib to trastuzumab and capecitabine significantly extended PFS among patients with locally advanced unresectable or metastatic HER2-positive breast cancer, according to topline results of the randomized HER2CLIMB trial.

The FDA has granted neratinib orphan drug designation for the treatment of patients with breast cancer and brain metastases, according to a press release from the drug’s manufacturer.

Fulvestrant in combination with everolimus extended PFS significantly longer than fulvestrant with vistusertib or fulvestrant alone among women with hormone receptor-positive metastatic breast cancer, according to results of the randomized phase 2 MANTA trial published in JAMA Oncology.

California Institute for Regenerative Medicine awarded a $9.28 million grant will support a clinical trial at City of Hope to evaluate chimeric antigen receptor T-cell therapy for patients with HER2-positive breast cancer that spread to the brain.